CHMP anså den lave uønskede incidens inden for spektret hos opioidtolerante patienter for at være acceptabel og registrerede bemærkningen i produktresuméet om dosistitrering.
The CHMP considered the low adverse spectrum incidence in opioid-tolerant patients reassuring and noted the statement in the SPC on dose titration.